Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 127

Similar articles for PubMed (Select 16968947)

1.

The endocannabinoid system as an emerging target of pharmacotherapy.

Pacher P, Bátkai S, Kunos G.

Pharmacol Rev. 2006 Sep;58(3):389-462. Review.

2.

Pharmacotherapeutic targeting of the endocannabinoid signaling system: drugs for obesity and the metabolic syndrome.

Vemuri VK, Janero DR, Makriyannis A.

Physiol Behav. 2008 Mar 18;93(4-5):671-86. Epub 2007 Nov 21. Review.

3.

The endocannabinoid system as a target for the treatment of motor dysfunction.

Fernández-Ruiz J.

Br J Pharmacol. 2009 Apr;156(7):1029-40. doi: 10.1111/j.1476-5381.2008.00088.x. Epub 2009 Feb 13. Review.

4.

In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability.

Giuffrida A, McMahon LR.

Prostaglandins Other Lipid Mediat. 2010 Apr;91(3-4):90-103. doi: 10.1016/j.prostaglandins.2009.05.004. Epub 2009 Jun 10. Review.

5.

Therapeutic potential of cannabinoids in CNS disease.

Croxford JL.

CNS Drugs. 2003;17(3):179-202. Review.

PMID:
12617697
7.

Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.

Hwang J, Adamson C, Butler D, Janero DR, Makriyannis A, Bahr BA.

Life Sci. 2010 Apr 10;86(15-16):615-23. doi: 10.1016/j.lfs.2009.06.003. Epub 2009 Jun 13. Review.

8.

The endocannabinoid system and pain.

Guindon J, Hohmann AG.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):403-21. Review.

9.

The emerging role of the endocannabinoid system in cardiovascular disease.

Pacher P, Steffens S.

Semin Immunopathol. 2009 Jun;31(1):63-77. doi: 10.1007/s00281-009-0145-8. Epub 2009 Apr 9. Review.

10.

Modulating the endocannabinoid system in human health and disease--successes and failures.

Pacher P, Kunos G.

FEBS J. 2013 May;280(9):1918-43. doi: 10.1111/febs.12260. Epub 2013 Apr 22. Review.

11.

Cannabinoid receptors and their ligands.

Pertwee RG, Ross RA.

Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):101-21. Review.

PMID:
12052030
12.

Targeting CB2 receptors and the endocannabinoid system for the treatment of pain.

Anand P, Whiteside G, Fowler CJ, Hohmann AG.

Brain Res Rev. 2009 Apr;60(1):255-66. doi: 10.1016/j.brainresrev.2008.12.003. Epub 2008 Dec 25. Review.

PMID:
19150370
13.

Role of the endocannabinoid system in the development of tolerance to alcohol.

Basavarajappa BS, Hungund BL.

Alcohol Alcohol. 2005 Jan-Feb;40(1):15-24. Epub 2004 Nov 18. Review.

14.
15.

Cannabinoids.

Grotenhermen F.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):507-30. Review.

PMID:
16266285
17.
18.

The emerging role of the endocannabinoid system in endocrine regulation and energy balance.

Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R.

Endocr Rev. 2006 Feb;27(1):73-100. Epub 2005 Nov 23. Review.

PMID:
16306385
19.

Cannabinoid receptors as therapeutic targets.

Mackie K.

Annu Rev Pharmacol Toxicol. 2006;46:101-22. Review.

PMID:
16402900
20.

Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain.

Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, Cravatt BF, Lichtman AH.

J Pharmacol Exp Ther. 2009 Sep;330(3):902-10. doi: 10.1124/jpet.109.155465. Epub 2009 Jun 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk